Pfizer Will Pay $42.9 Million to Settle Unfair Marketing Charges Related to Zyvox, Lyrica
Pfizer Inc. (PFE) agreed to pay a combined $42.9 million to North Carolina and 32 other states in a settlement of allegations that the drug maker used unfair and deceptive practices in the marketing of antibiotic Zyvox and nerve-pain medicine Lyrica.
A Pfizer spokesman wasn't immediately available to comment.
The states had alleged that Pfizer had marketed Zyvox as superior to another antibiotic in fighting certain types of infections, though there allegedly wasn't substantial evidence to support superior results for some uses that Pfizer claimed.
The states also alleged that Pfizer marketed Lyrica for some off-label, or unapproved, uses. While doctors can prescribe medications for such off-label uses, it is illegal for drug makers to market treatments for uses that haven't been approved by the U.S. Food and Drug Administration.
The $42.9 million settlement includes a $1.3 million payment to North Carolina.